BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $59.00 +2.88%
Revenue Growth %: +13.2%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +13.2%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.91, $0.38 better than the analyst estimate of $0.53. Revenue for the quarter came in at $746 million versus the consensus estimate of $703.14 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.25-$3.35, versus the consensus of $3.22. BioMarin Pharma sees FY2024 revenue of $2.79-2.825 billion, versus the consensus of $2.799 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gulfport Energy and Mobility Global to join S&P SmallCap 600
- TEN Holdings prices $7.5 million common stock offering at $1 per share
- Select Medical stockholders approve buyout by insider-led consortium
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
